Newsroom

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Dr. Brady’s conversation with Andreas Argyrides, Managing Director, Senior Biotech...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Executive Appointments...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical study data supporting the potential safety and long-term efficacy of PBGENE-DMD has been selected as a poster presentation at the upcoming 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference taking plac...

NEW YORK--(BUSINESS WIRE)--Moody's Corporation (NYSE: MCO) today announced results for the fourth quarter and full year 2025 and provided its outlook for full year 2026. The Fourth Quarter and Full Year 2025 Earnings Release and other earnings materials can be found on the Moody’s IR website at ir.moodys.com. In addition, the Earnings Release will be furnished with the Securities and Exchange Commission (SEC) on a Form 8-K and will be available on the SEC website at www.sec.gov. Teleconference...

SOUTH BURLINGTON, Vt.--(BUSINESS WIRE)--BETA Technologies, Inc. (NYSE: BETA) (“BETA” or “the Company”), an electric aerospace company, today announced it will release its financial results for the fourth quarter and full year 2025 before the market opens on March 9, 2026. The Company will also host a live webcast beginning at 8:30 a.m. ET to discuss the results. A live webcast and supporting materials can be accessed here. All participants joining by telephone should register by clicking here f...

NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--Perion Network Ltd. (NASDAQ and TASE: PERI), an advanced technology leader solving for the complexities of digital advertising through AI-native execution infrastructure, today reported its financial results for the fourth quarter and full year ended December 31, 2025. “Our fourth-quarter performance, highlighted by a 19% year-over-year increase in Contribution ex-TAC and a 53% surge in Adjusted EBITDA, demonstrates that Perion One is winning,” said...

NEW YORK & MELBOURNE, Australia--(BUSINESS WIRE)--Radformation, a leading provider of intelligent automation solutions for radiation oncology, and Icon Group (Icon), a leading global integrated cancer care provider, today announced the initial deployment of ChartCheck Adaptive, Radformation’s Offline Adaptive Assessment solution, across 15 cancer centres in Australia. The rollout reflects the growing clinical value of automated adaptive assessment workflows within routine radiotherapy practice....

MONTRÉAL--(BUSINESS WIRE)--Nouveau Monde Graphite Inc. (« NMG » ou la « Société ») (NYSE : NMG, TSX : NOU) se prépare à la construction de la mine Matawinie de la phase 2, désignée par le gouvernement du Canada comme un grand projet d’intérêt national, via l’acquisition de capacités de construction, de services, d’équipements et de matériaux clés. Les principaux contrats attribués au cours des derniers mois, assortis de dispositions rendant leur pleine exécution conditionnelle à l’obtention d’u...

MONTRÉAL--(BUSINESS WIRE)--Nouveau Monde Graphite Inc. (“NMG” or the “Company”) (NYSE: NMG, TSX: NOU) is preparing for the construction of its Phase-2 Matawinie Mine – a major project of national interest as identified by the Government of Canada – via the procurement of key construction capacity, services, equipment and materials. Major contracts awarded over the past few months, with provisions for full execution upon the Company having reached a positive final investment decision (“FID”), re...

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, Feb. 24, 2026, at 3:30 p.m. ET, featuring Kevin M. Flanigan, MD, the Wolfe Foundation Endowed Chair in Neuromuscular Research at Nationwide Children’s Hospital and professor of pediatrics an...